MODELING THE COST-EFFECTIVENESS OF USTEKINUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN US

被引：1
|
作者：
Verma, S. [1 ]
Dharmarajan, S. [1 ]
Yang, Y. [1 ]
机构：
[1] Univ Mississippi, University, MS 38677 USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72715-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A147 / A147
页数：1
相关论文
共 50 条
  • [41] BUDGET-IMPACT AND COST-EFFECTIVENESS OF TILDRAKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM A US HEALTH PLAN PERSPECTIVE
    Carrico, J.
    Jia, X.
    Zhao, Y.
    Zhang, J.
    Brodtkorb, T. H.
    Mendelsohn, A. B.
    Lowry, S.
    Wu, J. J.
    Feldman, S. R.
    Armstrong, A. W.
    [J]. VALUE IN HEALTH, 2019, 22 : S52 - S52
  • [42] Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis
    Ferrandiz, C.
    Garcia, A.
    Blasco, A. J.
    Lazaro, P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (06) : 768 - 777
  • [43] Cost per treated patient for etanercept and ustekinumab in patients treated for moderate to severe plaque psoriasis
    Shah, Neel
    Harrison, David
    Wu, Ning
    Lee, Yuan-Chi
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB166 - AB166
  • [44] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB FOR THE TREATMENT OF ADULTS WITH MILD-TO-MODERATE PLAQUE PSORIASIS REFRACTORY TO OTHER BIOLOGIC AGENTS IN MEXICO
    Salazar, A.
    Aguirre, A.
    Flores, R.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A245 - A245
  • [45] A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A55 - A55
  • [46] COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GERMANY
    Betts, K.
    Yan, Y.
    Sundaram, M.
    Hengst, N.
    Wolff, M.
    Bensimon, A. G.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A570 - A570
  • [47] Cost-Effectiveness of Biological Therapy in the Remission Induction of moderate and severe Psoriasis
    Radtke, M. A.
    Schmitt-Rau, K. H.
    Rosenbach, T.
    Augustin, M.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 192 - 192
  • [48] Comparative cost-effectiveness for tildrakizumab and other targeted therapies for the treatment of moderate to severe plaque psoriasis in the United States
    Jia, Xiaoying
    Mendelsohn, Alan
    Zhang, Jingchuan
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Zhao, Yang
    Feldman, Steven
    Armstrong, April
    Wu, Jashin J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB80 - AB80
  • [49] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO CURRENT BIOLOGICS SEQUENCES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN FRANCE
    Duteil, E.
    Cariou, C.
    Schmidt, A.
    Benjamin, K.
    Duco, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A589 - A589
  • [50] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
    Moreno, S.
    Walsh, S.
    Khanna, P. J.
    Jain, M.
    Tanova-Yotova, N.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
12345